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Purpose/Objective: The deaths due to radiation pneumonitis and 
fibrosis seen in the lethally-irradiated victims of the Tokai-mura 
incident form part of the characteristic spectrum of outcomes seen in 
late responding tissues that make up the radiation-induced multi-
organ dysfunction syndrome (RI-MODS). Additionally, we have 
identified an increased sensitivity in previously irradiated animals to 
otherwise survivable insults experienced in the months to years post-
injury, with a differential response between those animals irradiated 
as adults versus neonates; we believe that this precipitated 
susceptibility may be mechanistically similar to overt RI-MODS. These 
observations have led us to incorporate multiple organs/endpoints, 
delayed insult and age into a screening system for testing potential 
mitigation agents for use in both accidental and therapeutic 
scenarios. 
Materials and Methods: Our group has developed an integrated 
preclinical testing system that, although individually focused on 
separate organs of interest, nonetheless, is integrated through 
common radiation delivery systems, drug delivery protocols and 
assessment tools. Murine models investigating the delayed radiation 
response in lung, the central nervous system, erythropoietic bone 
marrow, skin and immune systems have been developed and verified. 
Mitigating agents are delivered no earlier than 3 days post-radiation 
and models are followed for up to 18 months prior to sacrifice. 
Results: A number of agents now have undergone preliminary testing 
using our model, including agents targeted at free radicals, 
inflammation, as well as specific signaling molecules. Early results 
indicate the utility of this system in identifying potential efficacy in 
individual organs or tissues, as well as, importantly, possible areas of 
clinical concern. Both the model and critical drug data will be 
presented. 
Conclusions: There is a significant need for the development of 
agents targeted at delayed radiation-induced effects in the context of 
whole body irradiation. We have introduced a preclinical testing 
system that provides a broad test-bed for screening potential 
mitigation candidates. Importantly, its focus on several critical organs 
allows for multiple endpoints to be assessed, thereby allowing for 
broad spectrum mitigation strategies to be developed, whilst allowing 
for the identification of possible areas of toxicity that may adversely 
affect and/or limit wide-scale treatment protocols. Furthermore, 
through this system, we have identified sensitivity to secondary, 
delayed insults (e.g. trauma, infection), particularly in special 
populations, such as children, suggesting that multiple treatment 
strategies may need to be developed dependent on age at time of 
irradiation.  
This work was supported by the Center for Medical Counter measures 
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Purpose/Objective: Adjuvant treatment of breast cancer is commonly 
associated with the development of pulmonary injury and 
inflammation. The aim of the study was to investigate changes in 
serum levels of surfactant protein-D (SP-D), a potential specific 
marker of lung disease, during postoperative breast cancer therapy 
incorporating irradiation combined with administration of trastuzumab 
or hormone therapy. 
Materials and Methods: A total of 38 patients with primary breast 
cancer, aged between 30 and 76 years (median = 51.5 years), were 
monitored throughout a three-month period starting prior to the 
initiation of radiation therapy (RT) and until two months after the 
completion of RT. Serum levels of SP-D were serially determined at 
four predefined time-points in all patients and 31 healthy controls, 
using enzyme linked immunosorbent assay. All assays were performed 
in duplicates. 
Results: No disease progression was observed after clinical 
examination, radiological imaging and quantitative assessment of 
cancer markers CEA and CA 15-3. Pre-radiotherapy levels of SP-D were 
significantly higher in breast cancer patients compared to healthy 
controls (p=0.0240). Serum SP-D expression exhibited a gradual 
increase during adjuvant therapy (p=0.0032). More specifically, a 
significant increase in SP-D levels was observed in patients treated 
with a combination of radiotherapy and trastuzumab (p=0.0310). SP-D 
levels exhibited a significantly lower rate of change in patients under 
treatment with irradiation and hormone therapy (p=0.0428). 
Conclusions: SP-D is abundantly produced by pulmonary alveolar type 
II and Clara cells, thus its corresponding circulating levels can 
effectively reflect alterations in the alveolar compartments and 
epithelium. In the absence of clinical and imaging evidence of acute 
therapy-induced complications, our observations of the rate of change 
of serum SP-D expression indicate that the combined administration of 
RT and trastuzumab in breast cancer patients is likely to be associated 
with the development of subclinical pulmonary inflammation. On the 
contrary, treatment with radiation and hormone therapy appears to 
exert a protective effect against pulmonary toxicity.  
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Purpose/Objective: To provide a dose-volume response analysis of 
patient-reported urinary incontinence after external beam radiation 
therapy (EBRT) for prostate cancer. 
Materials and Methods: The study population consisted of 302 long-
term prostate-cancer survivors who had been treated with pelvic 
radiation therapy to a total dose of 70 Gy at 2 Gy per fraction at the 
Sahlgrenska University Hospital in Sweden during 1993 – 2006 and 332 
non-irradiated control men from the Swedish Population Registry 
matched for age and residency. We used reactivated treatment data 
and delineated the entire urinary bladder following its outer contour 
to be able to export and analyse bladder dose-volume histograms. 
Patient-reported outcomes (PROs) were taken from a study-specific, 
validated, postal questionnaire including information on 
demographics, disease, treatment, quality of life and physical health 
including urinary symptoms [1]. Urinary incontinence was defined as 
'urinary leakage, more than a few drops, weekly or more often during 
the last six months'(cf. LENT-SOMA Grade 1-2 toxicity for 
bladder/urethra). We used Logistic regression to investigate a possible 
causal relationship between dose and the studied outcome. Dose-
volume response modelling was performed using the Logistic function 
with mean absorbed and fractionation-corrected dose (EQD2,3using the 
Linear-quadratic model with an α/β=3).Model was fitted to data using 
the maximum likelihood method with parameter confidence intervals 
(CIs) calculated with profile likelihood estimation. Using a grid-search, 
the dose parameter where probability of outcome is 50% (D50)was 
considered in increments of 0.1 Gy; the curve steepness parameter 
where probability of outcome is 50% (γ50) was considered in 
increments of 0.01. 
[1] Alsadius D., Radiother Oncol., 2011 Dec; 101(3):495-501. 
Results: The median follow-up for survivors was 7 years (range, 1 to 
14 years). Among the survivors, 15% reported incontinence versus 7% 
of the controls (prevalence ratio: 2.1, 95% CI: 1.3-3.4). Both absorbed 
and fractionation-corrected mean dose were significant predictors for 
the outcome (P=0.008 and P=0.011,respectively). The mean dose 
model including the control background symptom rate of 7% resulted 
in D50-values of 94.1 Gy for absorbed dose and 99.4 Gy3 for 
fractionation-corrected dose (68% CI: 81.5-123.3 and 83.5-139.0, 
respectively). Corresponding γ50-values were 1.14 and 1.02 (68% CI: 
0.87-1.47 and 0.79-1.31, respectively). 
